The Rise of GLP-1s in Youth: Evidence, Risks and Treatment Considerations

The rapid expansion of GLP-1 receptor agonist prescribing for pediatric weight management has outpaced long-term outcome data and clinical consensus. This presentation offers a rigorous, evidence-based review of current research on GLP-1 use in children and adolescents, including efficacy, safety, durability of weight outcomes, and the known - and still emerging - implications of longer-term treatment. 

Beyond pharmacologic considerations, the session will examine how weight bias influences clinical decision-making and its measurable impact on pediatric mental health, eating behaviors, and treatment engagement. Participants will leave with a balanced, developmentally informed framework to support ethical, patient-centered prescribing and interdisciplinary collaboration. 

The target audience for this continuing education program is mental health providers and clinicians working with individuals with mental health diagnoses. Materials are appropriate for learners with an introductory level of understanding about mental health concerns.  

Educational Objectives:  

Following this presentation, participants will be able to… 

• Summarize current evidence regarding the efficacy, safety, and durability of GLP-1 receptor agonists for weight management in children and adolescents.
• Analyze how weight bias influences prescribing practices, patient experiences, and mental health outcomes in youth.
• Evaluate potential short- and long-term risks and benefits associated with GLP-1 use in pediatric populations.  

Questions about this event? Please email Continuing.Education@ERCPathlight.com